175 related articles for article (PubMed ID: 35867199)
1. Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.
Fouqueray P; Chevalier C; Bolze S
Clin Drug Investig; 2022 Sep; 42(9):721-732. PubMed ID: 35867199
[TBL] [Abstract][Full Text] [Related]
2. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Dubourg J; Ueki K; Grouin JM; Fouqueray P
Diabetes Obes Metab; 2021 Mar; 23(3):800-810. PubMed ID: 33275318
[TBL] [Abstract][Full Text] [Related]
4. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
Pirags V; Lebovitz H; Fouqueray P
Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.
Chevalier C; Dubourg J; Bolze S; Fouqueray P
Clin Pharmacokinet; 2021 Apr; 60(4):485-490. PubMed ID: 33169345
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects.
Willen D; Uhl W; Wolna P; Papasouliotis O; Yalkinoglu Ö
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):27-40. PubMed ID: 31529406
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Shibata M; Hatta T; Saito M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Clin Drug Investig; 2020 May; 40(5):469-484. PubMed ID: 32274653
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
[TBL] [Abstract][Full Text] [Related]
12. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
13. Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.
Chevalier C; Perrimond-Dauchy S; Dubourg J; Fouqueray P; Bolze S
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):725-733. PubMed ID: 32860624
[TBL] [Abstract][Full Text] [Related]
14. A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects.
Ermer J; Martin P; Corcoran M; Matsuo Y
Neuropsychopharmacol Rep; 2020 Mar; 40(1):16-29. PubMed ID: 31765110
[TBL] [Abstract][Full Text] [Related]
15. Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.
Tomita Y; Hansson E; Mazuir F; Wellhagen GJ; Ooi QX; Mezzalana E; Kitamura A; Nemoto D; Bolze S
Clin Transl Sci; 2022 Apr; 15(4):1014-1026. PubMed ID: 34962074
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects.
Cawello W; Kim SR; Braun M; Elshoff JP; Ikeda J; Funaki T
Clin Drug Investig; 2014 Feb; 34(2):95-105. PubMed ID: 24178238
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.
Iitsuka H; Tokuno T; Amada Y; Matsushima H; Katashima M; Sawamoto T; Takusagawa S; van Gelderen M; Tanaka T; Miyahara H
Clin Drug Investig; 2014 Jan; 34(1):27-35. PubMed ID: 24178236
[TBL] [Abstract][Full Text] [Related]
18. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers.
Teng R; Butler K
Int J Clin Pharmacol Ther; 2014 Jun; 52(6):478-91. PubMed ID: 24755129
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
